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Abstract
Laboratory models support an inverse association between
anti-M€ullerian hormone (AMH) and breast tumor development.
Human studies are lacking; one study (N ¼ 105 cases, 204
controls) with prospectively collected serum reported the oppo-
site—an approximate 10-fold increase in breast cancer risk com-
paring fourth with first quartile AMH levels. We investigated the
relation between serum AMH levels and breast cancer risk in a
case–control (N ¼ 452 cases, 902 controls) study nested within
the prospective Sister Study cohort of 50,884 women. At enroll-
ment, participants were ages 35 to 54, premenopausal, and
completed questionnaires onmedical and family history, lifestyle
factors, and demographics. AMH (ng/mL) was measured by
ultrasensitive ELISA in serum collected at enrollment and log-
transformed for analysis. Multivariate conditional logistic regres-
sion was used to calculate ORs and 95% confidence intervals (CI)
to account for matching on age and enrollment year. Mean age at
enrollment was 46.8 years with an average 2.9 years from blood
draw to breast cancer diagnosis (SD ¼ 1.9). AMH concentrations
were below the limit of detection (0.003 ng/mL) for approxi-
mately 25% of samples. Compared with samples below the LOD,
womenwithAMH>2.84ng/mL (90thpercentile among controls)
had a 2-fold increase in breast cancer odds (OR, 2.25; 95% CI,
1.26–4.02). For each 1-unit increase in lnAMH, overall breast
cancer odds increased by 8% (OR, 1.08; 95% CI, 1.02–1.15) and
odds of estrogen receptor–positive, invasive disease increased by
15%(OR, 1.15; 95%CI, 1.05–1.25).Ourfindings demonstrate an
overall positive relation between AMH and breast cancer. Cancer
Prev Res; 8(6); 528–34. 2015 AACR.
Introduction
Anti-M€ullerian hormone (AMH), also called M€ullerian inhibit-
ing substance (MIS), is a peptide hormone produced by the gran-
ulosa cells of pre- and small antral ovarian follicles, and is amember
of the TGFb family (1). Named for its role in M€ullerian duct
regression during the embryologic development of male fetuses,
AMH is clinically used in adult women as a measure of ovarian
reserve. Low circulating levels of AMH can be used to inform the
potential success of fertility treatments, and high levels are associ-
ated with conditions such as polycystic ovary syndrome (2).
Available evidence suggests that AMH levels peak in the mid-
20s and decline thereafter, becoming nondetectable an estimated
5 to 6 years before menopause (3–5). Unlike other ovarian-
produced hormones, including estrogen and progesterone, AMH
levels are relatively stable across the menstrual cycle (2). Labora-
tory-based cell line and mouse models demonstrate an inverse
relationship between AMH and breast tumor development and
growth through activation of the NFkB signaling cascade (6–9).
However, these models reflect a basal-like breast cancer subtype
that accounts for only 15% to20%ofbreast cancers—themajority
of tumors are luminal subtypes characterized, in part, by expres-
sion of estrogen or progesterone receptors (10, 11). A single
prospective case–control study in humans (N ¼ 105 cases, 204
controls) observed a 9.8-fold increase in breast cancer risk (95%
CI, 3.3–28.9) comparing fourth with first quartile AMH levels
from archived samples donated at a mean age of 45 years (12).
Although the distribution of tumor subtypes was not evaluated,
the mean age at diagnosis (59 years) suggests that the majority
were likely luminal tumors (12).
Because of the lower incidence rate of breast cancer among
reproductive-age women (13) and the large sample sizes required
for studying the effects of AMH prospectively, there has been
limited available evidence to substantiate this observed associa-
tion since its publication in 2009. In a 2011 cross-sectional
clinical study of 30 women ages 38 to 50 undergoing breast
biopsy, lower AMH levels were found among those with a
coincident cancer (14). In a 2013 case–control study (N ¼ 108
cases, 99 controls), therewas nooverall associationbetweenAMH
and breast cancer (15). For the two latter studies, AMH measure-
ment was performed concurrent with or subsequent to cancer
diagnosis and may not reflect relative levels before tumor
development.
To prospectively study the relation between serum AMH levels
and breast cancer risk, we conducted a case–control study (N ¼
452 cases, 902 controls) nested within the Sister Study cohort of
50,884 women.
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Materials and Methods
The Sister Study prospective cohort was designed to address
genetic and environmental risk factors for breast cancer. During
2003 to 2009, 50,884U.S. and Puerto Ricanwomen ages 35 to 74
were recruited through a national multimedia campaign and
network of recruitment volunteers, breast cancer professionals,
and advocates. Eligible women had a sister who had been diag-
nosed with breast cancer but did not have breast cancer them-
selves. This research was approved by the Institutional Review
Boards of the National Institute of Environmental Health
Sciences, NIH, and the Copernicus Group. All participants pro-
vided informed consent.
At enrollment, participants completed baseline questionnaires
on medical and family history, lifestyle factors, and demo-
graphics. Blood samples were collected during a home visit by
trained phlebotomists and shipped overnight to the Sister Study
laboratory where they were processed to obtain serum and stored
at 80C.
Study design
To be eligible for selection in the current case–control study,
Sister Study participants were required to be ages 35 to 54 at
enrollment, have an archived serum sample from the enrollment
visit, have at least 1 intact ovary, and be categorized as premen-
opausal. Premenopausal status was defined as reporting one or
more menstrual cycles in the prior 12-month period on the
enrollment questionnaire. Women whose only reason for not
experiencingmenses was hysterectomy (without bilateral oopho-
rectomy) were categorized as premenopausal based on age 55.
Among eligible participants, we identified 461 incident breast
cancers diagnosed between enrollment and December 31, 2012.
Breast cancer diagnoses were initially self-reported and then
confirmed bymedical record abstraction. For each identified case,
two control participantswhodidnot have a reported breast cancer
diagnosis as of the corresponding case's diagnosis date were
matched according to age (within 5 months) and year of study
enrollment. Of the identified cases, 458 (99%) had sufficient
archived serum for analysis. Of the matched controls, 4 had
insufficient available sample and were replaced. In total, samples
from 458 cases, and 916 controls were analyzed for AMH levels.
We further excluded three cases who were determined after
medical record review to have benign breast conditions, 2 cases
with missing diagnosis dates, and 1 case with a low-quality
sample (and their matched controls). We also excluded two
controls (matched to different cases) due to prior prophylactic
bilateral mastectomy or low-quality sample. Ultimately, 452
breast cancer cases and 902 controls contributed to these analyses.
Laboratory assays
All assays were performed at the Reproductive Endocrinology
laboratory at theUniversity of Southern California Keck School of
Medicine. Case–control trios were analyzed together in the same
batch. AMHwasmeasured primarily using anUltrasensitive AMH
ELISA kit (Ansh Labs). The picoAMH ELISA Kit (Ansh Labs) was
used when AMH values were below the limit of detection (LOD)
of the Ultrasensitive ELISA (<0.07 ng/mL). The LOD of the
picoAMH ELISA is 0.003 ng/mL. Of the 1,354 samples, 484
(154 cases, 330 controls) did not have detectable levels by the
Ultrasensitive ELISA and were analyzed by the picoAMH ELISA.
Of these, 130 (47 cases, 83 controls) had detectable concentra-
tions using the picoAMH. The manufacturer-specified interassay
coefficients of variation are as follows: 4.6%, 4.8%, and 2.0% at
0.346, 0.715, and 1.85 ng/mL, respectively, for the Ultrasensitive
AMH assay, and 4.5%, 2.2%, and 3.8% at 22.6, 86.5, and 373
pg/mL, for the picoAMH assays. In our study, blinded control
samples (mean ¼ 1.89 ng/mL) were run in duplicate in the first
39 batches with interassay CVs of 14.5%. Testosterone was
measured by radioimmunoassay with preceding organic solvent
extraction and Celite column partition chromatography (16).
The assay sensitivity is 1.5 ng/dL and the interassay CVs are 8%,
12%, and 12% at 13, 30, and 96 ng/dL, respectively.
Statistical analysis
Serum AMH levels were skewed with a long tail to the right;
therefore, natural log-transformed values were calculated to
approximate a normal distribution for analysis as a continuous
variable. When analyzed as a continuous variable, AMH samples
that fell below the detectable range were imputed as 0.0015
ng/mL (the midpoint between 0 and the LOD, 0.003 ng/mL).
AMHcategorieswere defined as samples below the LOD, and at the
25th, 50th, 75th, and 90th percentiles among controls.Quartiles of
total testosterone were defined on the basis of the distribution of
controls with the first quartile set as the reference category.
Age-adjusted geometric means for natural log-transformed
AMH were calculated using generalized linear regression models
according to characteristics among control participants. We used
LOESS smoothing with local quadratic regression to descriptively
model the relationship between age and AMH separately for cases
and controls.
To account for the matched case–control design, we used
multivariable conditional logistic regression, conditioned on the
matched sets, to calculate ORs and 95% confidence intervals (CI)
for breast cancer. Potential confounders were identified a priori
from the breast cancer and AMH literature and evaluated in age-
controlled models. Final statistical models accounted for age and
enrollment year through matching and adjusted for age at men-
arche (continuous), current oral contraceptive use (yes/no),
smoking status (never/former/current), parity, and breastfeeding
(nulliparous/parous, never breastfed/parous, breastfed), body
mass index (BMI; underweight: <18.5 kg/m2, normal: 18.5–
24.9 kg/m2, overweight: 25.0–29.9 kg/m2, obese  30.0 kg/m2),
and total testosterone (ln ng/dL) as potential confounders.
To statistically evaluate trends, we included select variables in
regressionmodels as continuous linear termsor categorical ordinal
terms, and report P values and the Ptrend, respectively. To test for
effect modification by age at diagnosis (<45 vs.45) and estrogen
receptor (ER) status (positive vs. negative), we included cross-
product interaction terms in conditional logistic models and
report the Pinteraction. Although ER status is an attribute of cases,
to test for interaction ER status is held constant at the level of
the matched set (17, 18). The interpretation of the interaction test
is, therefore, whether the association between AMH and case
status is differential in matched sets where the case is ER positive
versus ER negative. All statistical analyses were performed with
Sister Study Data Release 3.2 (August 2014) using SAS 9.3 (SAS
Institute, Inc.).
Results
Study participant characteristics according to case–control sta-
tus are provided in Table 1. The average age at study enrollment
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and blood draw for breast cancer cases (and matched controls)
was 46.8 years. Compared with control participants, a higher
proportion of breast cancer cases reported currently using oral
contraceptives (10.6% vs. 7.0%) and being nulliparous (25.0%
vs. 21.7%), whereas a lower proportion reported currently smok-
ing (5.8% vs. 8.4%).
Geometric means for serum AMH levels according to select
characteristics among control participants are displayed in Fig. 1.
AMH levels declinedwith increasing age at blooddraw (P<0.001)
and were lower among women with younger ages at menarche
(P ¼ 0.02) and current oral contraceptive users (P ¼ 0.002). BMI
had aU-shaped association with AMH: womenwith underweight
and obese BMIs had lower AMH than those in the normal to
overweight range (P ¼ 0.04). Prior hysterectomy or oophorecto-
my was associated with lower AMH levels compared with women
without a hysterectomyor unilateral oophorectomy (0.04 vs. 0.08
ng/mL for each; P  0.02). Although not statistically significant,
AMH concentrations appeared lower among current cigarette
smokers compared with never smokers, higher with increasing
quartiles of total testosterone, and among womenwith polycystic
ovary syndrome. Parity and breastfeeding were not associated
with mean AMH.
The average time from blood draw to breast cancer diagnosis
was 2.9 years (SD ¼ 1.9; range, 1 month–8.4 years). Approxi-
mately 25% of samples had undetectable AMH levels (Table 2);
increasing from 2% of cases and controls ages 35 to 40 to 54%
to 57% of cases and controls ages 50 to 54 at blood draw. AMH
levels according to age at blood draw among cases and controls,
and the number of samples below the LOD by case and control
status, are provided in Fig. 2.
Overall, we observed a positive linear trend between increasing
serumAMH levels and breast cancer odds (Table 1–3). Compared
with women with AMH values below the LOD (0.003 ng/mL),
women with AMH >2.84 ng/mL (the 90th percentile among
controls) had an approximate 2-fold increase in breast cancer
odds (OR, 2.25; 95% CI, 1.26–4.02). For each 1-unit increase in
lnAMH, breast cancer odds increased by 8% (OR, 1.08; 95% CI,
1.02–1.15; Table 2–3). In sensitivity analyses restricted to women
with an intact uterus (N ¼ 394 cases, 777 controls), women with
intact ovaries (N ¼ 431 cases, 848 controls) or who were not
currently using oral contraceptives (N¼ 404 cases, 839 controls),
effect estimates for the association between continuous lnAMH
and breast cancer risk were virtually unchanged (OR, 1.09; 95%
CI, 1.02–1.17; OR, 1.08; 95% CI, 1.01–1014; and OR, 1.09; 95%
CI, 1.03–1.16, respectively).
The positive trend between lnAMH and breast cancer odds was
not strongly influenced by multivariate adjustment for age at
menarche, current oral contraceptive use, smoking status, parity
and breastfeeding, BMI, or total testosterone levels (Table 2). In
breast cancer models stratified according to ER expression, the
positive trend with AMH remained elevated for ER-positive
tumors (OR, 1.12; 95% CI, 1.04–1.20), but not ER-negative
tumors (OR, 1.02; 95% CI, 0.87–1.19). This difference in the
association between AMH and breast cancer according to ER
status was not statistically significant by formal interaction tests
(Pinteraction ¼ 0.1). Similarly, a positive trend with AMH concen-
trations was observed for women with breast cancer diagnosed at
ages 46 to 50 and 51 to 60 (OR, 1.12; 95%CI, 1.02–1.23 andOR,
1.11; 95% CI, 1.02–1.22, respectively), but was not statistically
significantly different from diagnosis ages 35 to 45 (OR, 0.95;
95% CI, 0.91–1.11; Pinteraction ¼ 0.2). The association between
AMH and breast cancer appeared similar for invasive (OR, 1.10;
95% CI, 1.02–1.18) and ductal carcinoma in situ disease (DCIS,
OR, 1.06; 95% CI, 0.93–1.20; Table 3). We further evaluated
the potential influence of time from blood draw to diagnosis on
AMH associations with breast cancer. Estimates for tumors diag-
nosed within 2 years of blood draw versus >2 years were similar
(Table 3).
Discussion
In our sample of women diagnosed with breast cancer at ages
35 to 60, prediagnosis serum AMH levels were positively associ-
ated with breast cancer risk compared with age-matched controls.
The positive trend appeared strongest for women diagnosed at
older ages with ER-positive tumors, although interaction tests
with age and ER status were not statistically significant.
Previous experimental studies have suggested that AMH may
play an important role in breast cancer risk. AMH receptors (MIS
type II) are expressed in both normal and cancerous breast tissue.
Contrary to our findings, several in vitro and in vivo studies have
shownAMHcan inhibit tumor cell growth andmigration through
NFkB-mediated pathways (8, 9, 19). However, these studies have
Table 1. Study participant characteristics among 452 breast cancer cases and
902 controls, Sister Study, 2003–2009
Breast cancer
cases Controls
Age at enrollment, mean (y; SD) 46.8 (4.4) 46.8 (4.4)
Age at menarche, y
<12 86 19.0 178 19.7
12 133 29.4 239 26.5
13 131 29.0 243 26.9
14 94 20.8 240 26.6
Currently using oral contraceptives, N (%)
No 404 89.4 839 93.0
Yes 48 10.6 63 7.0
Smoking status, N (%)
Never 288 63.7 554 61.4
Former 138 30.5 272 30.2
Current 26 5.8 76 8.4
Parity and breastfeeding, N (%)
Nulliparous 113 25.0 196 21.7
Parous, never breastfed 70 15.5 132 14.6
Parous, breastfed 269 59.5 573 63.5
BMI (kg/m2), N (%)
<18.5 4 0.9 14 1.6
18.5–24.9 205 45.4 397 44.0
25–29.9 137 30.3 248 27.5
30 106 23.5 242 26.8
Total testosterone (ng/dL), N (%)
20 90 19.9 204 22.6
20.1–27 118 26.1 236 26.2
27.1–35 119 26.3 231 25.6
35.1 116 25.7 219 24.3
Undetectable/insufficient sample 9 2.0 12 1.3
Hysterectomy, N (%)a
No 394 87.2 777 86.1
Yes 58 12.8 125 13.9
Unilateral oophorectomy, N (%)a
No 431 95.4 848 94.0
Yes 21 4.6 54 6.0
Polycystic ovary syndrome (PCOS), N (%)
No 434 96.0 872 96.7
Yes 18 4.0 27 3.0
aAll women were required to have 1 intact ovary for selection into the nested
case–control study.
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focused on basal-like breast cancer models such as the C3Tag
mouse model or the MCF10A cell line, and therefore may not be
comparable with a study examining all breast cancers. Basal-like
breast cancers represent only 15% to 20%of breast cancers overall
(10, 11, 20), and distinct effects in those tumors would not be
readily detectable in our sample, which included amajority of ER-
positive breast cancers
Although basal-like breast cancer represents the minority of
tumors overall, basal-like subtypes are proportionally more com-
monamong youngerwomen (e.g., 26.5%of tumors at ages 40–49
vs. 17.5% at ages 60–69 in Sweeney and colleagues; ref. 21).
Epidemiologic studies of AMH and breast cancer diagnosed at
reproductive ages are lacking. A cross-sectional studyof 30women
ages 38 to 50 undergoing breast biopsies found lower AMH levels
(P¼ 0.0009) amongwomenwith a cancer finding versus a benign
diagnosis (14). A case–control study (N¼ 108 cases, 99 controls)
using post-diagnosis, pretreatment serum samples reported
no overall association between mean AMH and breast cancer,
but an inverse association among women diagnosed after age
37 (b ¼ 0.85, 95% CI, 1.48 to 0.22). These findings are
consistentwith the laboratory data, but the small sample sizes and
use of AMHmeasures collected concurrently or after breast cancer
diagnosis are problematic for evaluating AMH as a predictive
factor. Other elements of the case–control study design also limit
interpretation: Cases were identified from oncology clinics in
Pennsylvania and California, whereas controls were North Car-
olina residents participating in a fecundability study. Further-
more, the median age at enrollment was 40.2 years among cases
and 33.9 among controls (15).
One prior epidemiologic study analyzed prediagnosis AMH
concentrations in relation to breast cancer risk, and unlike the
other reports, observed a positive association between AMH and
breast cancer risk (12). Using a nested case–control design (N ¼
108 cases, 99 controls), AMH concentrations were measured in
archived blood samples donated at an average age of 45 years.
After a mean follow-up of 14 years, 105 breast cancers were
diagnosed. The authors reported a 9.8-fold increase in breast
cancer odds comparing fourth versus first quartile AMH (OR,
Figure 1.
Age-adjusted AMH concentrations
among 902 control participants
according to select characteristics,
Sister Study 2003–2009. The
reference line indicates the overall
geometric mean of AMH
concentrations among controls.
All women were required to have
1 intact ovary for selection into the
nested case–control study.
Anti-M€ullerian Hormone and Breast Cancer Risk
www.aacrjournals.org Cancer Prev Res; 8(6) June 2015 531
Research. 
on July 14, 2020. © 2015 American Association for Cancercancerpreventionresearch.aacrjournals.org Downloaded from 
Published OnlineFirst April 14, 2015; DOI: 10.1158/1940-6207.CAPR-14-0377 
9.8; 95% CI, 3.3–28.9). This effect was most apparent among
women diagnosed at ages 55 years (12).
On the basis of the laboratory models and few human studies,
wehypothesized that thedirect effect of circulatingAMHonbreast
tissue would be antitumorigenic such that higher levels of AMH
would be associatedwith decreased risk for premenopausal breast
cancer, whereas higher relative levels of AMH before menopause
would be positively associated with older-onset breast cancer as a
marker of delayed menopause, an established breast cancer risk
factor. In our analysis, we were unable to identify the hypothe-
sized inverse association except by the weak, nonsignificant
association among women diagnosed with breast cancer at ages
35 to 45. However, only 64 cases were characterized as ER-
negative, and only a subset of these would likely meet the full
definition of the basal-like subtype (10, 11).
The increased risk of breast cancer among older women with
higher AMH may reflect an older age at menopause. As noted
above, AMH is produced by the granulosa cells of pre- and small
antral ovarian follicles. As the number of ovarian follicles is
depleted over the life course, AMH levels decline until they become
undetectable beforemenopause. In the PennOvarian Aging Study,
women ages 35 to 48 with undetectable AMH concentrations
(lower LOD ¼ 0.10 ng/mL) had a median time to menopause of
6 years (3). Similarly, the longitudinal Michigan Bone Health and
Metabolism study demonstrated undetectable (<0.17 ng/mL)
AMH concentrations approximately 5 years before the final men-
strualperiod(3). In these studies andothers (22,23),higher relative
AMH concentration was a marker for delayed menopause (2, 24)
within a given age group. Older menopausal age confers a small,
but consistently observed, increase in breast cancer odds. In Nor-
wegian registry data, a 1-year difference in menopausal age was
estimated to confer a 4% increase in breast cancer odds (25).
Overall, our findings agree with the prior report by Dorgan and
colleagues, although the magnitude of the positive association is
smaller in our study. In the Dorgan study, control participants
were matched 2:1 to the cases on age and other factors and were
selected from a pool of premenopausal women based on men-
strual status and serum follicle–stimulating hormone and estra-
diol concentrations. In contrast, our study was not restricted to
women with hormone levels consistent with premenopausal
status. Instead, we relied upon self-report of one or menstrual
cycles in the previous 12 months, a common definition for
menopausal status in large epidemiologic studies (26). Further-
more, for women who reported a prior hysterectomy without
removal of both ovaries, we applied an age-based cutoff of <55
years to identify potentially premenopausal women. These crite-
ria may lead to some misclassification of menopausal status and
the possible inclusion of peri- or post-menopausal women. On
the basis of our definition ofmenopause, our analytic population
likely had a lower distribution of AMH levels compared with the
study population in theDorgan and colleagues report. Consistent
with Dorgan and colleagues, we observed a stronger effect esti-
mate among women diagnosed at older ages. Furthermore, we
observed the same pattern of association in sensitivity analyses
that excluded women with a prior hysterectomy where the mis-
classification of menopausal status is likely greatest.





(N ¼ 902) OR (95% CI)a OR (95% CI)b
AMH (ng/mL)
Nondetectable 107 247 1 1
0.003–0.10 78 166 1.16 (0.81–1.67) 1.23 (0.84–1.81)
0.10–0.37 88 166 1.39 (0.94–2.06) 1.56 (1.04–2.35)
0.38–1.17 85 162 1.44 (0.96–2.15) 1.56 (1.02–2.39)
1.17–2.84 52 96 1.60 (0.98–2.64) 1.81 (1.08–3.05)
>2.84 42 65 1.96 (1.13–3.40) 2.25 (1.26–4.02)
Ptrend (categorical AMH) 1.13 (1.03–1.25) 1.16 (1.05–1.29)
P (continuous lnAMH) 1.06 (1.01–1.13) 1.08 (1.02–1.15)
aAdjusted for age and enrollment year through matching.
bAdditionally adjusted for age at menarche, current oral contraceptive use,
smoking status, parity, breastfeeding, BMI, and total testosterone.
Figure 2.
AMH values according to age at blood
draw among breast cancer cases and
controls, Sister Study, 2003–2009.
Thenumber of samples below theLOD
are shown according to case and
control status (e.g., 1 case and 0
controls below the LOD at age 35 and
17 cases and 41 controls below the
LOD at age 54).
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Newly developed, ultrasensitive AMH assays allow for high-
quality AMH measurement at older reproductive ages and were
used in this analysis (27, 28). Nevertheless, we observed an increas-
ing proportion of samples with nondetectable levels with increas-
ing age from 35 to 54–50% of women 50 and older had non-
detectable values. AMH levels are relatively stable across the men-
strual cycle (2), and therefore are amenable tomeasurement in large
epidemiologic cohorts, like the Sister Study, where blood draws are
not timed to themenstrual cycle. However, one study of 27women
reported greater variability in AMH across the menstrual cycle at
ages 45 to 55 years comparedwith 18 to 35 years (29); if variability
is greater at older reproductive ages, our effect estimates could be
biased toward the null due to exposure misclassification.
Testosterone levels have less variability across the menstrual
cycle comparedwith estradiol and progesterone and are positively
associated with pre- and post-menopausal breast cancer (30).
Testosterone concentrations are also positively correlated with
AMH levels (31, 32) and were controlled for in the current
analysis. We did not measure estradiol levels because the blood
draw was not timed to the menstrual cycle and premenopausal
estradiol has a weaker association with breast cancer risk com-
paredwith postmenopausal levels (30, 33, 34). In theDorgan and
colleagues report, additional adjustment for estradiol did not
influence the association between AMH and breast cancer (12).
In our study, where 75% of breast cancers were diagnosed after
age 45 and 81% were ER positive, we observed a positive asso-
ciation between prospectively collected serum AMH and breast
cancer risk. A larger sample of women with a younger age
distribution or higher proportion of basal-like tumors is needed
to conclusively address possible protective effects of AMH on
breast cancer. Quantifying expression of AMH receptors in breast
tissue and polymorphisms in the AMH and AMH type II receptor
genesmay also provide amore complete picture of the underlying
biology in future studies.
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